Flavor Preference and Systemic Immunoglobulin Responses in E-Cigarette Users and Waterpipe and Tobacco Smokers: A Pilot Study.
biomarkers
e-cigarette
flavors
immune response
motivation
respiratory symptoms
Journal
International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455
Informations de publication
Date de publication:
19 01 2020
19 01 2020
Historique:
received:
13
11
2019
revised:
07
01
2020
accepted:
16
01
2020
entrez:
23
1
2020
pubmed:
23
1
2020
medline:
17
7
2020
Statut:
epublish
Résumé
Electronic cigarette (e-cigarette) use has had an exponential increase in popularity since the product was released to the public. Currently, there is a lack of human studies that assess different biomarker levels. This pilot study attempts to link e-cigarette and other tobacco product usage with clinical respiratory symptoms and immunoglobulin response. Subjects completed surveys in order to collect self-reported data on tobacco product flavor preferences. Along with this, plasma samples were collected to test for immunoglobulin G (IgG) and E (IgE) levels. Our pilot study's cohort had a 47.9% flavor preference towards fruit flavors and a 63.1% preference to more sweet flavors. E-cigarette and traditional cigarette smokers were the two subject groups to report the most clinical symptoms. E-cigarette users also had a significant increase in plasma IgE levels compared to non-tobacco users 1, and dual users had a significant increase in plasma IgG compared to non-tobacco users 2, cigarette smokers, and waterpipe smokers. Our pilot study showed that users have a preference toward fruit and more sweet flavors and that e-cigarette and dual use resulted in an augmented systemic immune response.
Identifiants
pubmed: 31963835
pii: ijerph17020640
doi: 10.3390/ijerph17020640
pmc: PMC7013586
pii:
doi:
Substances chimiques
Flavoring Agents
0
Immunoglobulin G
0
Immunoglobulin E
37341-29-0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIEHS NIH HHS
ID : T32 ES007026
Pays : United States
Organisme : NHLBI NIH HHS
ID : 1R01HL135613
Pays : United States
Organisme : NCI NIH HHS
ID : U54CA228110
Pays : United States
Références
Chest. 2012 Jun;141(6):1400-1406
pubmed: 22194587
J Calif Dent Assoc. 2019 Feb;47(2):85-92
pubmed: 30976150
JAMA. 2019 Nov 5;:
pubmed: 31688891
Eur Respir J. 2001 Apr;17(4):773-90
pubmed: 11401076
Toxicol Res. 2014 Mar;30(1):13-8
pubmed: 24795794
ERJ Open Res. 2019 Dec 23;5(4):
pubmed: 31886159
Int J Environ Res Public Health. 2009 Jan;6(1):209-24
pubmed: 19440278
J Clin Pathol. 1997 Oct;50(10):819-22
pubmed: 9462262
J Hazard Mater. 2018 Feb 15;344:549-557
pubmed: 29102637
Nat Rev Cardiol. 2017 Aug;14(8):447-456
pubmed: 28332500
J Med Internet Res. 2018 Mar 12;20(3):e80
pubmed: 29530840
J Allergy Clin Immunol. 1985 May;75(5):594-8
pubmed: 3989144
Int J Chron Obstruct Pulmon Dis. 2015 Jul 21;10:1409-16
pubmed: 26229460
J Environ Pathol Toxicol Oncol. 2016;35(4):343-354
pubmed: 27992314
Am Rev Respir Dis. 1981 Nov;124(5):523-5
pubmed: 7305105
PLoS One. 2018 Jul 9;13(7):e0198047
pubmed: 29985948
Oral Oncol. 2016 Jan;52:58-65
pubmed: 26547127
Tob Control. 2020 Mar;29(2):140-147
pubmed: 30760629
Am J Respir Crit Care Med. 2018 Feb 15;197(4):492-501
pubmed: 29053025
Drug Alcohol Depend. 2019 Mar 1;196:9-13
pubmed: 30658221
Monaldi Arch Chest Dis. 2005 Dec;63(4):213-25
pubmed: 16454221
Ky J Commun. 2017;36(1):35-51
pubmed: 29805323
Tob Control. 2020 Feb;29(Suppl 2):s102-s109
pubmed: 31494573
Curr Opin Pulm Med. 2017 Mar;23(2):111-116
pubmed: 27906858